Navigation Links
BLU-MED Announces New Medical Preparedness Contracts
Date:11/30/2007

KIRKLAND, Wash., Nov. 30 /PRNewswire/ -- BLU-MED Response Systems announced today two new contract awards, worth over $850K combined, that will increase medical preparedness and surge capacity for hospitals and public health systems in the State of Idaho's Health Department District Four and Suffolk County, NY.

The first contract, for three Rapidly Deployable Medical Response Systems, was awarded by the Idaho Central District Health Department. This contract includes customized BLU-MED deployable medical shelters, HVAC and electrical systems, generators and ancillary support units. In addition to the portable medical shelters and equipment, BLU-MED will provide training and technical support services for the Central District Health Department in Idaho in early 2008. The state-of-the-art BLU-MED shelter systems will be used to boost medical surge capacity in the event of pandemic influenza, bioterrorism, or other mass casualty incident.

The second contract, awarded by the Suffolk County Fire Rescue and Emergency Services agency, is for two Rapidly Deployable Medical Response Systems. Suffolk County will have access to these BLU-MED RapidSurge Systems full-scale emergency medical shelters that have been upgraded with negative pressure isolation capacity, a decontamination system, and a complete latrine package.

"These systems will offer great flexibility in meeting both Idaho's and Suffolk County's public health needs in a disaster or emergency," said president of BLU-MED Response Systems Gerrit Boyle. "They can be utilized to provide space for hospital surge capacity, medical isolation and large scale immunizations, as well as, extra capacity for triage and evaluation at the scene of an incident."

The new BLU-MED Response contracts will add Idaho and Suffolk County, NY to a growing list of states, counties and municipalities that are building their preparedness for large-scale public health emergencies. "We are pleased to assist the
'/>"/>

SOURCE BLU-MED Response Systems
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. BLU-MED Response Systems Announces New Production Facility in Idaho
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2008)...ents freedom of movement, better quality of life ,... An automated artificial kidney that can be worn ...at the insulin pump is to diabetes patients. , ...orks better than conventional dialysis, according ...xperimental Nephrology . , "What,s really new a...
(Date:7/25/2008)...wswire-USNewswire/ -- Anthony Shih,M.D., M.P.H., ...e President,of Strategic Planning, after a two-yea...ation committed to improving U.S. health system pe...ram on Health Care Quality,Improvement and Efficie.../20080725/DC28791LOGO ), Board-certified in publ...
(Date:7/25/2008)...troviral therapy may be due to genetic factors , ...ew study challenges the long-held belief that the ...s ability to restore itself after HIV patients are... (HAART). , From 50 percent to 90 percent of HI...Intravenous drug use is the main cause of both typ...
(Date:7/25/2008)...sumers tips and encourages them to, ,Speak Up,(TM...uly 25 /PRNewswire-USNewswire/ -- The Pennsylvania... Patient Safety Day" which,is a national effort to...ate fully in their healthcare by asking questions ...ry or illness., "We understand the important role...
Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3
...again in UK when it has been hit by a virus the se...farm in Yorkshire//. The Centre for Environment F...sed a report that states that scientists are study...ausing viral Haemorrhagic Septicaemia (VHS). <...
...archers at the University of Wisconsin-Madison it ... have more to pay later. // Super-sized meals whi... calories which help a person to gain more weight....s, health care and more. An average upsized fast-...
...al Center, has said that awareness needs to be cre...anger. // It has stated that it is not the program...anger of falling TV sets. UT Southwestern pediatri...ency department cases involving children injured b...
...BA) have entered into a partnership to support a g... The campaign, 'Unite for Children, Unite against...S on children as well as impeding further spread o...ow that our sport, indeed all sports, has an enorm...
Other Medicine News:Health News:Adults Needs to be Educated About the Dangers of Elevated TVs 2
(Date:7/23/2008)... July 23 /- InCode BioPharmaceutics, ... announced preclinical test,results demonstrating ...,the treatment of the rare chronic blood disorder ...plete results will be presented at the XXII,Intern... September 28,2008., The only treatment currentl...
(Date:7/23/2008)...d on IND-Enabling Work with Protein Therapeutics t...lement System, CAMBRIDGE, Mass., July 23 /PRNewsw...it has initiated a corporate growth plan with the,...cutive officer and the,establishment of its headqu...oodruff Emlen, M.D., a co-founder of the company w...
(Date:7/22/2008)...acy results from a multi-center 293-patient Europe... Stock Exchange Symbol: CYT, MONTREAL, July 22 /P...c., the global leader in cryotherapy products to t...ults previously presented from three,European stud... Front(R),were published earlier today in the Jou...
(Date:7/22/2008)...under Therapeutics Development Initiative bring MJ... next deadline January 20,2009, NEW YORK, July 2...n to,speed delivery of transformative treatments a...Fox Foundation for Parkinson,s Research has awarde...search teams. The awards,were granted under MJFF,s...
Breaking Medicine Technology:InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 1Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 2Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 3Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 4Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 4267 1Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 4267 2Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 4267 3Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 1Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 2Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 3Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 4Field Museum Launches Shared Bike Program for Employees 15487 1Field Museum Launches Shared Bike Program for Employees 15487 2
...SINESS WIRE)--Jun 5, 2007 - NovaDel Pharma,Inc. (A...loping,oral spray formulations for a broad range o...o clinical studies comparing zolpidem,oral spray w...cokinetic (PK), pharmacodynamic (PD) and safety ob...as Ambien(R), a leading,drug for the treatment of ...
... III Study Results Presented At ASCO -- , CHICAGO ...ith,pegylated interferon alfa-2b in stage III mela...apse-free survival (RFS),according to the results...atients with stage III melanoma. Results of the Ph...r the Research and,Treatment of Cancer (EORTC) and...
Other Medicine Technology:NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 2NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 3NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 4NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 5NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 6NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 7Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 2Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 3Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 4Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 5
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
Medicine Products: